US 11,738,056 B2
Compositions and methods for improving mitochondrial function
Gary Ruvkun, Newton, MA (US); J. Amaranath Govindan, Somerville, MA (US); and Elamparithi Jayamani, Boston, MA (US)
Assigned to THE GENERAL HOSPITAL CORPORATION, Boston, MA (US)
Filed by THE GENERAL HOSPITAL CORPORATION, Boston, MA (US)
Filed on Mar. 9, 2021, as Appl. No. 17/196,271.
Application 17/196,271 is a continuation of application No. 16/293,789, filed on Mar. 6, 2019, granted, now 10,973,860.
Application 16/293,789 is a continuation of application No. PCT/US2019/014725, filed on Jan. 23, 2019.
Claims priority of provisional application 62/721,979, filed on Aug. 23, 2018.
Claims priority of provisional application 62/620,641, filed on Jan. 23, 2018.
Prior Publication US 2021/0213074 A1, Jul. 15, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/74 (2015.01); A61K 9/00 (2006.01); C12N 9/04 (2006.01); C12N 9/02 (2006.01); C07K 14/195 (2006.01); C12N 1/20 (2006.01); A23L 33/135 (2016.01); A23L 2/52 (2006.01); A23K 10/18 (2016.01)
CPC A61K 35/74 (2013.01) [A23K 10/18 (2016.05); A23L 2/52 (2013.01); A23L 33/135 (2016.08); A61K 9/0053 (2013.01); A61K 9/0056 (2013.01); C07K 14/195 (2013.01); C12N 1/20 (2013.01); C12N 9/0006 (2013.01); C12N 9/0055 (2013.01); C12N 9/0057 (2013.01); C12Y 101/99 (2013.01); C12Y 110/02002 (2013.01); C12Y 110/0301 (2013.01); A23V 2002/00 (2013.01); C07K 2319/00 (2013.01); C12N 2500/14 (2013.01); C12N 2500/16 (2013.01); C12N 2500/34 (2013.01)] 17 Claims
 
1. A method of treating Alzheimer's Disease, the method comprising:
administering to a subject at risk of or suffering from Alzheimer's Disease, a therapeutically effective amount of a composition, thereby reducing the severity of at least one symptom of Alzheimer's Disease compared to a subject without the administration, and
wherein the composition comprises:
a measured amount of a bacterial species that comprises and expresses nucleic acid sequences encoding membrane-bound PQQ-dependent glucose dehydrogenase (mGDH), ubiquinol-cytochrome c reductase iron-sulfur subunit, TonB-dependent receptor, carbon-nitrogen hydrolase, and ubiquinol oxidase subunit II, or an extract or fraction derived therefrom,
wherein the extract or fraction of the bacterial species comprises membrane-bound PQQ-dependent glucose dehydrogenase (mGDH), ubiquinol-cytochrome c reductase iron-sulfur subunit, TonB-dependent receptor, carbon-nitrogen hydrolase, and ubiquinol oxidase subunit II expressed from the nucleic acid sequences,
wherein the bacterial species is from the Acetobacteriaceae family.